Vertex Pharmaceuticals 2025: Revenue Growth Accelerates to 9% as New Product Launches Gain Traction

What happened

Vertex reported $12.0 billion in total revenues for 2025, representing 9% growth over 2024's $11.0 billion. The CF franchise remained the core driver, with TRIKAFTA/KAFTRIO generating $10.3 billion (up 1%) and newly launched ALYFTREK contributing $837.8 million. Other product revenues of $820.1 million included $115.8 million from CASGEVY gene therapy (reflecting 64 patient infusions during the year) and $59.6 million from JOURNAVX acute pain treatment. Operating income reached $4.2 billion compared to a $233 million loss in 2024, when the company recorded a $4.4 billion non-cash charge for the Alpine acquisition. In 2025, total R&D and SG&A expenses increased to $5.7 billion from $5.1 billion, driven by pipeline advancement and commercial launches. The company recorded a $379.0 million intangible asset impairment related to VX-264, its type 1 diabetes candidate that was discontinued after failing to meet its efficacy endpoint in a Phase 1/2 trial. Cost of sales as a percentage of net product revenues held relatively stable at 13.8% versus 13.9% in 2024, benefiting from ALYFTREK's lower royalty burden (4% versus 9.33% for TRIKAFTA) but facing headwinds from higher manufacturing costs for biologics and cell therapies. Operating cash flow turned strongly positive at $3.6 billion compared to negative $493 million in 2024, which had been impacted by the Alpine acquisition. Cash and marketable securities grew to $12.3 billion from $11.2 billion. The company initiated a $4.0 billion share repurchase program in May 2025, completing $618.5 million in buybacks by year-end.

Why it matters for investors

The 9% revenue growth demonstrates that Vertex's commercial engine is functioning across multiple products and disease areas, reducing dependence on TRIKAFTA/KAFTRIO as new launches contribute materially. ALYFTREK's $837.8 million contribution in its first full year validates the company's strategy to serially innovate within CF, while its lower royalty burden (4% versus 9.33% for TRIKAFTA) improves gross margin economics if the company successfully defends its royalty position against Royalty Pharma's claim of approximately 8%. The swing to $4.2 billion in operating income reflects normalized profitability after the prior year's Alpine acquisition charge. The return to strong operating cash flow generation of $3.6 billion provides capital to fund both pipeline advancement and capital return, as evidenced by the new $4.0 billion buyback authorization. The $379.0 million VX-264 impairment illustrates inherent clinical risk in the business model but also demonstrates management's willingness to terminate underperforming programs. The company's advancement of povetacicept toward accelerated approval, with rolling BLA submission initiated in Q4 2025, represents a meaningful near-term catalyst for revenue diversification beyond CF. CASGEVY's 64 patient infusions and 147 cell collections globally show execution progress in the complex cell therapy market, though the product's high cost of goods relative to revenue (as disclosed in risk factors) indicates this remains a margin headwind.

Key highlights

Vertex's financial performance in 2025 was characterized by accelerating revenue growth to 9% and a return to strong operating profitability following the prior year's Alpine acquisition charge. The company demonstrated commercial execution across multiple new products, with ALYFTREK contributing $837.8 million, CASGEVY reaching $115.8 million (64 patient infusions), and JOURNAVX generating $59.6 million in revenues. Operating cash flow of $3.6 billion represented a significant improvement from negative $493 million in 2024, supporting both pipeline investment and the new $4.0 billion share repurchase program. Cost of sales as a percentage of revenues remained relatively stable at 13.8%, benefiting from ALYFTREK's lower royalty burden but facing headwinds from higher manufacturing costs for biologics and cell therapies. The company faced setbacks including the discontinuation of VX-264 for type 1 diabetes, resulting in a $379.0 million impairment charge, and an ongoing arbitration with Royalty Pharma over ALYFTREK royalty rates that could impact future gross margins. On the pipeline front, povetacicept advanced toward potential accelerated approval in IgA nephropathy with rolling BLA submission initiated in Q4 2025, representing a meaningful near-term catalyst. The effective tax rate normalized to 14.9% in 2025 from an anomalous 315.5% in 2024 that had been distorted by the non-deductible Alpine acquisition charge.

Management commentary

Management stated they expect total revenues to increase in 2026 due to continued growth of CF product revenues, including from ALYFTREK globally, and increased contributions from CASGEVY and JOURNAVX. They anticipate cost of sales as a percentage of net product revenues to increase due to a higher proportion of products outside CF, which currently have greater manufacturing costs relative to their net product revenue contributions, and continued investments in efficient manufacturing and delivery processes. Management expects development expenses to continue to increase in 2026 due to advancing pipeline programs, including type 1 diabetes programs. The company intends to continue investing in research programs with a focus on creating transformative medicines for serious diseases. Management emphasized their strategy to serially innovate in disease areas of interest and follow first-in-class therapies with potential best-in-class candidates to provide durable clinical and commercial success. Regarding ALYFTREK royalties, management stated they believe Royalty Pharma's position that the royalty burden is approximately 8% is contrary to the plain terms of the CFF Agreement and they intend to vigorously defend their position that it is 4%. Management highlighted that the majority of people with CF will transition to ALYFTREK over time. For CASGEVY, they noted that as of January 2026, approximately 90 percent of people with SCD or TDT in the U.S. have reimbursed access. Management disclosed they are using a priority review voucher to expedite the review of the povetacicept BLA from ten months to six months and expect to complete the full submission in the first half of 2026 if interim analysis data are supportive.

What to watch next

Investors should monitor:

• Resolution of the Royalty Pharma arbitration regarding ALYFTREK royalty rates (4% versus claimed ~8%), which could materially impact future gross margins and potentially require retroactive payments.

• Interim analysis data from the Phase 3 povetacicept trial in IgA nephropathy expected in the first half of 2026, which will determine whether the company completes the rolling BLA submission for potential accelerated approval.

• CASGEVY infusion volumes and cell collection trends in 2026, particularly following anticipated pediatric regulatory submissions for children 5 to 11 years of age in the first half of 2026 and reimbursement expansion.

• JOURNAVX commercial uptake trajectory as the company expands hospital formulary access beyond the current 100+ healthcare systems and seeks to grow coverage from the current two-thirds of U.S. covered lives.

• Enrollment completion in the AMPLITUDE Phase 2/3 trial of inaxaplin for APOL1-mediated kidney disease expected in the second half of 2026, and interim analysis data expected in late 2026 or early 2027.

This summary is based solely on excerpts from the company's Form 10-K filing.